The case study emphasizes the importance of CGP based on the biomarkers identified in the tumor in turn personalizing the cancer treatment to the patient.

This case demonstrates the importance of genetic testing in individuals presenting with non-classical syndrome like history.

This case demonstrates the value of CGP in NSCLC patients who do not harbour any well-known driver mutations in genes such as EGFR, KRAS, ALK, ROS1, RET, MET, and NTRK, instead harbour other targetable alterations that would potentially benefit the patient.

The case study on Leiomyosarcoma reveals CGP's ability to discover potential treatment options for progressive cancers that are recurrent.

This is a case which is unique in terms of how liquid biopsy could fail sometimes and tissue remains the gold standard for EGFR mutation status assessment.

This is a case which demonstrates the benefits of Comprehensive genome profiling by NGS in identifying biomarkers for therapy resistance in GIST. Providing therapies to GIST patients with KIT mutations once they have progressed on first and second lines of treatment and understanding the underlying mechanisms of resistance.

This is a case where Genetic testing was chosen by the consulting physician to determine potential therapeutic alternatives and the underlying cause of endocrine therapy resistance.